공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

세계의 남성 성선기능저하증 시장

Male Hypogonadism

리서치사 Global Industry Analysts, Inc.
발행일 2021년 04월 상품 코드 997505
페이지 정보 영문 182 Pages
가격
US $ 4,950 ₩ 5,625,000 PDF (Single User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste 가 되지 않으며, 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 PDF 라이선스 소유자로 한정됩니다.
US $ 14,850 ₩ 16,875,000 PDF (Global License to Company and its Fully-owned Subsidiaries) help
동일 기업 및 100% 자회사의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 남성 성선기능저하증 시장 Male Hypogonadism
발행일 : 2021년 04월 페이지 정보 : 영문 182 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 남성 성선기능저하증 시장 규모는 분석 기간(2020-2027년)에 2.9%의 연평균 복합 성장률(CAGR)로 확대될 전망이며, 2020년 28억 달러로부터, 2027년에는 35억 달러에 달할 것으로 예측됩니다.

본 보고서에서 분석한 부문 중 하나인 테스토스테론 대체요법(TRT)은 분석 기간 중 2.7%의 CAGR로 성장하고, 20억 달러에 달할 것으로 예측됩니다.

세계의 남성 성선기능저하증(Male Hypogonadism) 시장에 대해 조사했으며, 시장 점유율, 코로나19(COVID-19)의 영향, 동향과 성장요인, 지역별 시장 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 전해드립니다.

조사 대상 기업 예

  • AbbVie, Inc.
  • Allergan PLC
  • AstraZeneca PLC
  • Bayer AG
  • Eli Lilly and Company
  • Endo International PLC
  • Ferring International Center SA
  • IBSA Institut Biochimique SA
  • Laboratoires Genevrier
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.

목차

I. 조사 방법

II. 개요

  • 시장 개요
    • 인플루언서 시장 인사이트
    • 세계 시장 궤적
    • 코로나19(COVID-19)의 영향과 다가오는 세계 경기 침체
  • 주요 기업
  • 동향과 성장요인
  • 세계 시장 전망

III. 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

IV. 경쟁

  • 기업 개요 : 47개사
LSH 21.04.08

Abstract:

Global Male Hypogonadism Market to Reach $3.5 Billion by 2027

Amid the COVID-19 crisis, the global market for Male Hypogonadism estimated at US$2.8 Billion in the year 2020, is projected to reach a revised size of US$3.5 Billion by 2027, growing at aCAGR of 2.9% over the period 2020-2027. Testosterone Replacement Therapy, one of the segments analyzed in the report, is projected to record 2.7% CAGR and reach US$2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Gonadotropin & Gonadotropin Releasing Hormones Therapy segment is readjusted to a revised 3.2% CAGR for the next 7-year period.

The U.S. Market is Estimated at $830.8 Million, While China is Forecast to Grow at 2.8% CAGR

The Male Hypogonadism market in the U.S. is estimated at US$830.8 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$618.1 Million by the year 2027 trailing a CAGR of 2.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.7% and 2.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3% CAGR.

Select Competitors (Total 47 Featured) -

  • AbbVie, Inc.
  • Allergan PLC
  • AstraZeneca PLC
  • Bayer AG
  • Eli Lilly and Company
  • Endo International PLC
  • Ferring International Center SA
  • IBSA Institut Biochimique SA
  • Laboratoires Genevrier
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Male Hypogonadism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Male Hypogonadism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Male Hypogonadism by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Testosterone Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Testosterone Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Testosterone Replacement Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Gonadotropin & Gonadotropin Releasing Hormones Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Gonadotropin & Gonadotropin Releasing Hormones Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Gonadotropin & Gonadotropin Releasing Hormones Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Topical Gels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Topical Gels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Topical Gels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Injectables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Transdermal Patches by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Transdermal Patches by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Transdermal Patches by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Other Drug Deliveries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Other Drug Deliveries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Other Drug Deliveries by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 22: USA Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 23: USA Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: USA 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
    • TABLE 25: USA Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 26: USA Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: USA 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 28: Canada Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 29: Canada Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: Canada 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
    • TABLE 31: Canada Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 32: Canada Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: Canada 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 34: Japan Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 35: Japan Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: Japan 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
    • TABLE 37: Japan Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Japan Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: Japan 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 40: China Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 41: China Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: China 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
    • TABLE 43: China Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: China Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: China 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 46: Europe Current & Future Analysis for Male Hypogonadism by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 47: Europe Historic Review for Male Hypogonadism by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: Europe 15-Year Perspective for Male Hypogonadism by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 49: Europe Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Europe Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: Europe 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
    • TABLE 52: Europe Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Europe Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: Europe 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 55: France Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: France Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: France 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
    • TABLE 58: France Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 59: France Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 60: France 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 61: Germany Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Germany Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 63: Germany 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
    • TABLE 64: Germany Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Germany Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 66: Germany 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 67: Italy Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Italy Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 69: Italy 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
    • TABLE 70: Italy Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 71: Italy Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 72: Italy 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 73: UK Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: UK Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 75: UK 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
    • TABLE 76: UK Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 77: UK Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 78: UK 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 79: Rest of Europe Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Rest of Europe Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 81: Rest of Europe 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
    • TABLE 82: Rest of Europe Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Rest of Europe Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 84: Rest of Europe 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 85: Asia-Pacific Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Asia-Pacific Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 87: Asia-Pacific 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
    • TABLE 88: Asia-Pacific Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Asia-Pacific Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 90: Asia-Pacific 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • TABLE 91: Rest of World Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Rest of World Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 93: Rest of World 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
    • TABLE 94: Rest of World Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Rest of World Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 96: Rest of World 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 47
Back to Top
전화 문의
F A Q